CATX vs NVX

For growth investors, Novonix Limited (NVX) is the stronger pick with -51.

8% revenue growth year-over-year, versus -100. 0% for Perspective Therapeutics, Inc. (CATX). Analysts rate Perspective Therapeutics, Inc. (CATX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Perspective Therapeutics, Inc.

(CATX) delivered a total return of -59. 0%, compared to -96. 9% for Novonix Limited (NVX). Over 10 years, the gap is even starker: CATX returned -66. 4% versus NVX's -96. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Perspective Therapeutics, Inc.

(CATX) is the lower-risk stock at 1. 58β versus Novonix Limited's 1. 90β — meaning NVX is approximately 20% more volatile than CATX relative to the S&P 500. On balance sheet safety, Perspective Therapeutics, Inc. (CATX) carries a lower debt/equity ratio of 1% versus 51% for Novonix Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novonix Limited (NVX) is pulling ahead at -51.

8% versus -100. 0% for Perspective Therapeutics, Inc. (CATX). On earnings-per-share growth, the picture is similar: Novonix Limited grew EPS -7. 1% year-over-year, compared to -44. 7% for Perspective Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novonix Limited (NVX) is the more profitable company, earning -1278.

0% net margin versus -197. 3% for Perspective Therapeutics, Inc. — meaning it keeps -1278. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVX leads at -880. 0% versus -184. 6% for CATX. At the gross margin level — before operating expenses — NVX leads at 69. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Perspective Therapeutics, Inc.

(CATX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Novonix Limited (NVX) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CATX: -66. 4%, NVX: -96. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CATX (Healthcare) and NVX (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.